To the Editor-We read with interest the findings of Merrill et at. [1] that for zidovudine-resistant isolates of human immunodeficiency virus type 1 (HIV -1), the addition of zidovudine to stavudine antagonized the antiviral effect of stavudine in vitro as judged by inhibition of p24 antigen production. The combination of the two drugs was, however, synergistic against zidovudine-sensitive strains of HIV-1. These observations may be explained by interactions affecting intracellular phosphorylation of these agents. tion of zidovudine (mean, 5.79 pmol/Iu" cells), a reduction of some 41 % (table 1). Higher ratios of zidovudine to stavudine of 1:1 and 10: 1 resulted in reductions of 67% and 83%, respectively. On the other hand, zidovudine phosphorylation remained relatively unaffected by combination with stavudine (maximum inhibition of 23% at a concentration ratio of 1000; table 1). These observations are in keeping with data suggesting that thymidine kinase has a 600-fold lower affinity for stavudine than for zidovudine [2]. The combination of both nucleoside analogues thus results in diminished phosphorylation of stavudine without significantly affecting zidovudine phosphorylation. NOTE. Results are mean ± SD with n = 6 for ZDV and d4T anabolite formation.
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To the Editor-We read with interest the findings of Merrill et at. [1] that for zidovudine-resistant isolates of human immunodeficiency virus type 1 (HIV -1), the addition of zidovudine to stavudine antagonized the antiviral effect of stavudine in vitro as judged by inhibition of p24 antigen production. The combination of the two drugs was, however, synergistic against zidovudine-sensitive strains of HIV-1. These observations may be explained by interactions affecting intracellular phosphorylation of these agents. tion of zidovudine (mean, 5.79 pmol/Iu" cells), a reduction of some 41 % (table 1) . Higher ratios of zidovudine to stavudine of 1:1 and 10: 1 resulted in reductions of 67% and 83%, respectively. On the other hand, zidovudine phosphorylation remained relatively unaffected by combination with stavudine (maximum inhibition of 23% at a concentration ratio of 1000; table 1). These observations are in keeping with data suggesting that thymidine kinase has a 600-fold lower affinity for stavudine than for zidovudine [2] . The combination of both nucleoside analogues thus results in diminished phosphorylation of stavudine without significantly affecting zidovudine phosphorylation. NOTE. Results are mean ± SD with n = 6 for ZDV and d4T anabolite formation.
Data were analyzed by analysis of variance, followed by modified t test: P < *.01, t.OOI, t.05.
Zidovudine and stavudine are in direct competition for thymidine kinase during intracellular phosphorylation to their monophosphate metabolites, sharing a pathway that is distinct from that of other nucleoside analogues, such as didanosine, zalcitabine, and lamivudine [2] [3] [4] [5] [6] [7] [8] [9] . Peripheral blood mononuclear cells (PBMC) prestimulated with phytohemagglutinin (10 j..tg/mL, 72 h) were incubated with either eH]stavudine (0.65 jJCi, 3 jJM, 24 h) and zidovudine (0.3-30 j..tM) or eH]zidovudine (0.65 j..tCi, 0.02 j..tM, 5 h) and stavudine (0.2-20 J-lM). Cells were extracted overnight with 60% methanol prior to analysis by radiometric high-performance liquid chromatography as described [7] .
PBMC incubated with zidovudine (0.3 J-lM) and stavudine (3 j..tM), both within therapeutically achievable plasma concentrations, demonstrated fewer intracellular phosphate metabolites of stavudine (mean, 3.23 pmolll 0 6 cells) than was seen without addi-Merrill et al. [1] used a concentration ratio of zidovudine to stavudine of 0.05 when assessing the replication of the zidovudinesensitive isolate but a ratio of 1.2 against the zidovudine-resistant strain. On the basis of our in vitro phosphorylation data, it is clear that the formation of the active stavudine triphosphate anabolite will be markedly inhibited at a zidovudine-to-stavudine ratio of 1.2, but inhibition will be much less at a ratio of 0.05. We therefore suggest that the antagonism of the antiviral effect of stavudine by zidovudine in the resistant strain is due to competition for thymidine kinase and reduced stavudine phosphorylation. However, we also believe that if similar zidovudine-to-stavudine ratios (i.e., 1.2) had been used in the zidovudine-sensitive strain experiment, antagonism and not synergy would have been seen. The findings of Merrill et al. can be explained in relation to drug concentration rather than differences in HIV isolates.
We recognize that caution must always be exercised when applying in vitro findings to the clinical setting, particularly since zidovudine may still confer clinical benefit (e.g., in prevention of neurologic disease), even when peripheral isolates appear to be resistant.
Interactions that affect intracellular phosphorylation of nucleoside analogues are likely to be important in determining both the efficacy and toxicity of these drugs. The development of new
Reply
To the Editor-We agree with the suggestion of Hoggard et al. [1] that the antagonism of the antiviral effect of stavudine by zidovudine in our resistant human immunodeficiency virus type I (HIV-1) isolate may be due to competition for thymidine kinase and reduced stavudine phosphorylation, as their data suggest. Using the same zidovudine-to-stavudine ratio against the sensitive isolate is more problematic, however.
The central tenet of the median dose effect analysis of Chou and Talalay [2] for the determination of drug interactions is the assumed interchangeability of drug effects when expressed as a fraction of a given efficacy concentration. We choose to test compounds in equal proportions of their respective IC so in monotherapy. This technique allows for determination of a combination index (CI) for any fraction affected (Fa) by showing a single point on the isobologram representation of an Fa-CI plot of combined drug effects. Our technique is designed to determine the CI at the point of maximal divergence between the theoretical additive effect line and the experimentally obtained results. One could choose to use a different ratio, for example, 0.9X IC so of drug 1 in combination with 0.1 X IC so of drug 2; however, the interactive effect will be minimized as the axes of the isobologram are approached. Given the molar ratios of efficacy doses of zidovudine and stavudine of I:20 for our 14a-pre isolate, it would not be possible to determine interactive effects of the drugs at equimolar concentrations without drastically decreasing the sensitivity of the detection assay.
Ultimately, the situation in dually treated patients is much more complex than that in either our studies or those of Hoggard et al. [1] . Plasma and, more importantly, intracellular concentrations of drugs will vary widely, depending on such factors as drug doses, timing, distribution, and metabolism. Whether this will lead to clinical antagonism will be shown through carefully conducted trials, some of which are underway.
